INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

BACKGROUND: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of terlipressin, however, is hindered by the pau...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinberg, Ethan, Rahematpura, Suditi, Gonzalez, Stevan A., Izzy, Manhal J., Simonetto, Douglas A., Frederick, R. Todd, Rubin, Raymond A., Ikahihifo-Bender, Jade, Harte, Maggie, Kim-Lee, Grace, Witkiewicz, Sherry, Tobin, William, Jamil, Khurram, Fricker, Zachary, Reddy, K. Rajender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632660/
https://www.ncbi.nlm.nih.gov/pubmed/37953795
http://dx.doi.org/10.1016/j.conctc.2023.101211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632660/
https://www.ncbi.nlm.nih.gov/pubmed/37953795
http://dx.doi.org/10.1016/j.conctc.2023.101211

Ejemplares similares